The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

来自一项小规模临床试验的证据表明，一种称为CAR-T细胞的先进血癌免疫疗法的改进形式经调整后可能能够用于治疗重症肌无力（myasthenia gravis），即 ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

你是否曾经经历过这样的情况：浑身无力，眼皮抬不起，看东西时出现重影，甚至说话时鼻音变重？吃饭时越吃越累，日常的简单动作如刷牙、梳头都感到力不从心，走路时双腿像是绑着重物……如果你有这些症状，千万不要掉以轻心！因为这些看似简单的疲劳无力，可能隐藏着一种罕见疾病——重症肌无力（Myasthenia Gravis，简称MG）。

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

Myasthenia gravis is an autoimmune disorder causing muscle weakness that worsens with activity and improves with rest. It ...

Purpose Myasthenia gravis can cause variable strabismus with disabling diplopia and/or poor cosmesis. A retrospective study of a group of patients with myasthenia gravis or ‘myasthenia gravis ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

Myasthenia Gravis is a long-term, autoimmune condition in which the communication between muscles and nerves is impaired due to the production of certain antibodies resulting in voluntary muscle ...